Fundacion Clinic per a la Recerca Biomédica Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2011
NCT00860366
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Angel Chamorro, MD | Maria Joyera Rodríguez

Active Ingredients

Drugs in Phase 4 Trials (2)

dabigatran (pradaxa) (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Phase 3 Trials (3)

colchicine (colbenemid) (1 trial)

prednisone (meticorten) (1 trial)

uric acid (1 trial)

Drugs in Phase 2 Trials (1)

mrna-1273 (Spikevax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 3)

Hemorrhage (Phase 4)

Ischemia (Phase 3)

Stroke (Phase 3)

Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6